All members of the management and employees of Fujirebio work together under the corporate philosophy, “contributing to global healthcare through the creation of new values with respect for human life and commitment to people’s health,” to develop its business operations and outcomes as we endeavor to become an established global life science company.

We have made concrete efforts to meet diversifying customer needs with the core business of the fully automated chemiluminescent enzyme immunoassay system LUMIPULSE series (LUMIPULSE L2400, LUMIPULSE G1200 and LUMIPULSE G600II) and extensive product portfolio with the ESPLINE and ImmunoCard kit series consisting of immunoassay for influenza and other infectious diseases.

Active involvement with our global affiliates, Fujirebio Diagnostics, Inc. in the United States and Fujirebio Europe N.V. in Belgium has pressed forward the globalization of the LUMIPULSE business, while management integration of a domestic subsidiary, TFB Inc. was completed in April 2014. Such measures have carried out proactively to further strengthen the foundation of the business.

We will continue to enhance our corporate values and structure by promoting CSR (Corporate Social Responsibility) through environmental activities, strengthening information system, thorough compliance management and taking actions to improve productivity so that we can succeed through severe competition and establish our presence as a global life science company.

Environment surrounding healthcare is changing rapidly. Global healthcare in the 21st century is consistently trying to develop cure for intractable diseases and undertake reforms in clinical testing which can actualize more advanced diagnosis of malignant neoplasms and infectious diseases. While comprehensive and multinational cooperation is essential against Ebola hemorrhagic fever, avian influenza and other emerging pandemics, health concerns from social issues such as aging population, metabolic syndromes and asbestos are becoming more apparent mainly in Japan and other developed countries. Effective provision of earlier and more accurate diagnosis is critical to overcome these challenges, and clinical testing is expected to play an important role in society.

Fujirebio is determined to make valuable contribution to development of global healthcare and creating prosperous society through promptly addressing objectives to develop highly unique and competitive new products and to institute core technology for the next generation.

Yoshihiro Ashihara
President & CEO
Fujirebio Inc.
Corporate Philosophy

Contributing to Global Healthcare through the Creation of New Values with Respect for Human Life and Commitment to People’s Health

Management Policy

1. We place top priority on meeting our customers’ needs and providing them with highly reliable products, information and services.

2. We encourage our employees to develop their individual talents and expertise by providing a challenging and rewarding workplace environment that ensures equal employment opportunities and fair performance evaluations.

3. We strive to protect the environment and maintain good relationships with local communities.

4. We endeavor to live up to the trust of our shareholders through soundness and integrity of management.

Personal Information Protection Policy

Fujirebio Inc. (hereafter referred to as “the Company”) acknowledges its social responsibility to appropriately protect personal information (including Specific Personal Information). The Company shall address the protection of personal information based on the following policies and continuously strive to upgrade and improve its personal information protection system:

1. Compliance with laws and regulations pertaining to personal information protection
   When handling personal information, the Company shall comply with all relevant laws, such as the Act on the Protection of Personal Information and the Act on the Use of Numbers to Identify a Specific Individual in Administrative Procedures, as well as the guidelines and other rules established by the government.

2. Appropriate handling of personal information
   The Company shall clearly define the purpose of use of personal information to the extent necessary for business and acquire, use, and provide the personal information in an appropriate manner. The acquired personal information will be used within the limited scope of use, and the Company will implement preventive measures against unintended use.

3. Ensure the safety of personal information
   The Company shall implement legitimate safety and corrective measures to deal with the risks of unauthorized access to personal information and the loss, destruction, falsification and leakage of such personal information.

4. Request for disclosure of records of the handling of personal information and complaints
   The Company shall honestly and promptly respond to complaints and requests for the disclosure, correction, deletion, and suspension of use of personal information from the person.

Yoshihiro Ashihara
President & CEO
Fujirebio Inc.
As a research and development-oriented company, Fujirebio has always followed on innovation by creating highly unique products. In the immunoassay field, using its core technology, assays for infectious diseases including syphilis, hepatitis B, adult T-cell leukemia and Acquired Immunodeficiency Syndrome (AIDS) are widely contributing to society.

**Cultivating LUMIPULSE® to a globally recognized immunoassay system**

Since the fully automated chemiluminescent enzyme immunoassay system, LUMIPULSE 1200, was marketed in 1992 as the first model of the LUMIPULSE series, Fujirebio has been continuously developing new products on top of the current assay line of infectious diseases, tumor and various hormones markers. Among these new products, BNP test is presently recognized as a useful marker for differential diagnosis and screening for heart failure. HBsAg-Quant, a high sensitive HBsAg assay meanwhile foresees a great potential to be used for preventing reactivation of hepatitis B virus. The company also launched its vitamin D reagent in Europe and strengthened the product line which includes the proprietary assays.

LUMIPULSE G1200 was released on a worldwide basis in 2011. The model is currently available in the United States as well as many Asian and Western countries. A total of 1,500 units of LUMIPULSE models are in operation worldwide today, assisting routine testing at medical institutions and commercial clinical laboratories. Originated in Japan, the LUMIPULSE series has become a global brand of immunoassay systems.

---

**LUMIPULSE® L2400**

The highest-performance immunoassay systems with throughput of 240 tests per hour and simultaneous measurement 24 assays at a maximum. The compact system also features high expandability based on the external sampling and is easy to use.

**LUMIPULSE® G1200**

The system offers further convenience and excellent design flexibility on top of the credibility established by LUMIPULSE f (forte) with throughput of 120 tests per hour, simultaneous measurement of 24 assays at a maximum and a maximum of 36 assays on board.

**LUMIPULSE® G600II**

Data convertibility with other LUMIPULSE series can provide more accurate test results. Integrating the data processing unit to the body can make the system to minimize the space for its installation.
In November 2015, LUMIPULSE L2400 was also introduced. This new high-performance model can measure values for up to 24 assays simultaneously. LUMIPULSE L2400 was designed in accordance with legal restrictions of various countries and regions, so that it can be sold globally in the future. Furthermore, the LUMIPULSE series plays a vital role in screening of donated blood, as it has operated at the blood centers of the Japanese Red Cross Society since 2007 as its screening module.

Providing an extensive product line to support rapid diagnosis all year round

The ESPLINE series, by combining immunochromatography and EIA (Enzyme immunoassay), has simplified procedure and reduced assay time, and the influenza and HIV testing kit are highly recognized by doctors in hospitals and clinics all over Japan. In the ImmunoCard, ELNAS and other assay kits are also available, helping address the seasonal epidemic of pediatric infectious diseases throughout the year.

Venturing into a new field, urine analysis / blood coagulation and fibrinolysis analysis

The company has also entered the field of urinalysis with the iQ200 series, an effective and reliable automated analyzer for urine sediments using component images, as well as the iChem VELOCITY chemical urine analyzer. In May 2016, the STA R Max and STA Compact Max fully automated blood coagulation and fibrinolysis analyzers hit the market as well. The company has been working aggressively to expand to new fields so that it can meet diverse needs in the diagnostics industry.
Global leader in immunoserological testing

Fujirebio is the first company in the world to successfully commercialize a serological diagnostic reagent for syphilis, and launched its Treponema Pallidum Hemagglutination (TPHA) kit in 1966. Since the establishment in 1950, the company has supplied a wide range of clinical diagnostic products mainly for infectious diseases and tumors to medical institutions, commercial clinical laboratories and blood centers. Fujirebio’s products and services have expanded through its domestic and global subsidiaries. Fujirebio Diagnostics, Inc. (Pennsylvania, USA) has a competitive advantage in development and production of reagents as well as supplying of raw materials (antibodies) particularly for oncology testing. Fujirebio Europe N.V.(Belgium) specializes in development, production and sales of reagents in the area of infectious and Alzheimer’s disease segment.

As a global leader in immunoserological testing, Fujirebio’s R&D aims to improve the reliability, accuracy and speed of testing as well as product diversity in Japan, the US and Europe.
Offering reliable and extensive services and support

Fujirebio believes that the real service begins after the delivery of products to customers. Specially trained DMRs (Diagnostics Medical Representative) and TRs (Technical Support Services Representative) provide comprehensive support to customers including prompt assistance in cases of problems on our products. Technical and scientific information support is offered through Scientific Information Support Net on the website and Customer Call Center at the Shinagawa Office in Tokyo. Product Support Group has been established at the Hachioji plant which investigates any aspect of various problems reported by customers. Partnership with Miraca Group assists the company to offer high quality and value-added services and support. Fujirebio strives to ensure the satisfaction and safety of its customers through company-wide teamwork.

For efficient and cost-effective laboratory management

Healthcare is facing increasing pressures particularly from the growth of aging population with declining birth rate, revisions of the medical insurance system and changing public awareness. Fujirebio’s highly specialized staff draw on their medical consultancy background and years of experience to offer top quality services and expertise. The company works together with customers to develop better solution for their laboratory management to improve not only the quality of testing but also the cost and energy efficiency.

1995: GENEDIA HIV-1/2 Mix PA (clinical diagnostic reagent)

1996: LUMIPULSE f (forte) / CLEIA system
   The clinical testing and pharmaceutical division obtains ISO 9001, an international standard of quality management system. Fujirebio Europe B.V. (the Netherlands) is established.

2000: The company completes handover of its pharmaceutical business.

2001: LumiPulse® I TgAb and LumiPulse® I TPOAb (clinical diagnostic reagent)
   The company is accredited with ISO 13485, 9001, EN46001 and ISO 14001.

2005: LUMIPULSE® S and LUMIPULSE® Presto II (CLEIA system)
   The company becomes a holding company, Miraca Holdings Inc., as a consequence of the business integration of Fujirebio Inc. and SRL, Inc. and transfers its business to a newly established company, Fujirebio Inc.
   The company opens its representative office in Shanghai.

2006: MagStream HT (FOBT screening system)
   Nucleic-acid Amplification Testing (NAT) system

2007: The company starts distributing CL4800 (CLEIA system)
   to Japanese Red Cross Society.

2008: The company acquires 75% share of Advanced Life Science Institute,Inc. (currently a wholly owned subsidiary).

2010: The company acquires the whole ownership of Innogenetics N.V. (currently Fujirebio Europe N.V.)

2012: The head office is relocated to Shinjyuku-ku, Tokyo.

2014: LUMIPULSE® G600 II (CLEIA system)

2015: LUMIPULSE® L2400 (CLEIA system)
Meeting the world’s highest environmental and quality standards

Fujirebio has been proactively taking actions to achieve quality standards since 1993. The company obtained the certification of ISO9001, an international quality assurance in 1996 and ISO13485, an international quality management of medical devices in 2001 extending them to all operational sites in 2005. Commitment for environment and quality was also declared in 2001, and all locations of the company received the certification of ISO14001, an international standard for Environmental Management System (EMS).

Each member of Fujirebio takes initiatives to reinforce the awareness for environmental issues and quality control and to make continuous improvement for achieving world’s top-class environmental and quality standard.

Environment and Quality Declaration

Fujirebio takes all possible measures toward environmental protection and improvement and strives to achieve a symbiotic relationship with nature and the local communities. As a manufacturer of In-vitro Diagnostic products, we contribute to health care and life sciences worldwide. To ensure continued customer support and trust, all of our activities are conducted based on the following guidelines:

**Environmental Policy**

1. **Creation of Environmentally Friendly Products**
   In an effort to respect the environment at all levels of our activities (from product design to disposal), we endeavor to manufacture products that are environmentally friendly.

2. **Prevention and Abatement of Pollution**
   We actively confront the issues of pollution prevention and abatement by implementing thorough safety measures in the management of chemical and microbiological substances.

3. **Energy Saving, Resource Conservation and Recycling**
   All of our divisions are committed to reducing waste through the promotion of energy saving, resource conservation and recycling.

4. **Regulation Compliance**
   We fully observe and comply with all environmental protection laws, regulations, ordinances and agreements at national, regional and local levels.

5. **Review and advancement of Environmental Management System (EMS)**
   We periodically review environmental objectives and set goals to ensure the continuous advancement of EMS.

6. **Specification of Organization and Authority**
   Our written outline of specifications for the organization and authority concerning EMS constitutes the core around which all members of the company base their actions. We expect our partners to support the terms of this policy.

**Quality Policy**

1. We, employees and management of the Fujirebio Group, are committed to understanding the requirements and expectations of our customers, to thinking from their standpoint and to implementing all of our actions in compliance with the regulations and standards of each of the countries where we develop our business and export our products.

2. We are dedicated to providing our customers and their patients with safe and effective products, services and information of the highest quality.

3. We strive to maintain a progressive leadership in terms of the quality of all the products and services we provide.

4. We foster and uphold a strong quality-focused attitude throughout our organization and group company activity.

5. We promote the continual improvement of QMS in our entire organization.
Fujirebio gives thorough consideration to global environment because healthy earth is a premise to healthy life of human being, and all members of the company with support from its stakeholders come together to deliver environmentally friendly products and services.

The company sustainably contributes to environment mainly through the acquisition of ISO certification, compliance of environmental regulations and reduction of industrial wastes and CO₂ emission, which are presented in the annual environmental report. The report also includes Fujirebio’s environmental achievement directly from the business operations as well as indirectly resulted from the supply chain and other aspects of the business.

As global warming is one of the most important environmental issues, the company takes actions based on the mid-term environmental goal of reducing energy consumption and CO₂ emission while changing forest environment to improve CO₂ absorption.

Aiming for the best quality

Fujirebio ensures its quality policy throughout business operation including the R&D, manufacturing and sales department. Materials research and product development for both reagents and assay instruments at Hachioji Central Research Center and Obihiro Office and product processing and product control at Hachioji Plant, Sagamihara Plant and Ube Plant as well as support and maintenance services at all local offices are respectively controlled and managed with the rigorous quality standards to offer highly reliable products and services to customers.
Technical support for developing countries

As a social contribution activity, Fujirebio accepts trainees from countries in the Western Pacific, Southeast Asia and Africa through Japan International Cooperation Agency (JICA). Under this program, laboratory technicians and their supervisors from these countries learn how to diagnose Human Immunodeficiency Virus (HIV) infection. The company also exports its products to developing countries through WHO, UNICEF and other international organizations, thus contributing to healthcare in the world.

Returning profits to society

Fujirebio engages in academic and cultural activities based on the precept that “contribution to society must be at the root of corporate activities.” The company has sponsored the yearly Medicopia Educational Lecture Symposium, and issued the publication of the academic series “Medicopia” since 1981. Many participants attend the symposium each year for lectures and discussion on a wide range of medical issues with the main theme of Exchanging and Developing Clinical and Basic Medical Care. The company organizes a summer festival every year as a part of its local activity and interacts with local residents. Each office participates in voluntary cleanup activity in its local community.
Office Network

**Headquarters**
Shinjuku Mitsui Building 8th floor, 2-1-1 Nishishinjuku, Shinjuku-ku, Tokyo 163-0410
Tel. +81-3-6279-0800  Fax. +81-3-6279-0854

**Shinagawa Office**
Rivage Shinagawa 13th floor, 4-1-8 Kounan, Minato-ku, Tokyo 108-0075
Tel. +81-3-5781-3760  Fax. +81-3-5781-3761

**Hachioji Office**
51 Komiya-machi, Hachioji-shi, Tokyo 192-0031
Tel. +81-4-645-0071  Fax. +81-4-646-8325

**Hachioji 2nd Plant**
153 Komiya-machi, Hachioji-shi, Tokyo 192-0031
Tel. +81-4-646-4144  Fax. +81-4-646-4141

**Hachioji 3rd Plant**
935 Ishikawa-cho, Hachioji-shi, Tokyo 192-0032
Tel. +81-4-646-4118  Fax. +81-4-646-4133

**Sagamihara Plant**
1-3-14 Tanashi-cho, shu-ku, Sagamihara-shi, Kanagawa 252-0245
Tel. +81-4-711-8081  Fax. +81-4-711-8089

**Obihiro Office**
8-36 Nishi-3-ten, Aza Otouke, Otouke-cho, Katou-Gun, Hokkaido 080-0341
Tel. +81-155-32-4440  Fax. +81-155-32-4446

**Ube Office**
Setohara Danchi, 203-152 Aza Ushiwa, Oaza Yoshiwa, Ube-shi, Yamaguchi 759-0134
Tel. +81-836-62-1123  Fax. +81-836-62-1239

**Distribution Center**
1-17-19 Hajima-cho, Akishima-shi, Tokyo 196-0002
Tel. +81-4-546-6913  Fax. +81-4-546-6915

**Kuki Distribution Center**
SG Realty Kuki II 6th floor, 1662 Shimohayamamaya, Kuki-shi, Saitama 346-0022
Tel. +81-480-26-1133  Fax. +81-480-26-1134

**Tokyo Branch/Shuokenk Branch/Kanagawa Branch**
Rivage Shinagawa 13th floor, 4-1-8 Kounan, Minato-ku, Tokyo 108-0075
Tel. +81-3-5781-3760  Fax. +81-3-5781-3761

**Hokkaido Branch**
KDX Sapporo Building 5th floor, 4-1-2 Nishi, Kita-7-jo, Kita-ku, Sapporo-shi, Hokkaido 060-0807
Tel. +81-11-758-7000  Fax. +81-11-758-7002

**Tohoku Branch**
Aoi Nissei Dowa Sondeo Sendai Ichibancho Building 1st floor, 2-8-10 Ichiban-cho, Aoba-ku, Sendai-shi, Miyagi 980-0811
Tel. +81-22-264-4001  Fax. +81-22-264-4008

**Kita Kanto Branch**
Ichigo Omiya Building 5th floor, 2-81 Miya-cho, Omiya-ku, Saitama-shi, Saitama 330-0002
Tel. +81-48-643-0321  Fax. +81-48-644-2724

**Chubu Branch**
Dalwa Meiki Building 9th floor, 1-21-19 Meiki Minami, Nakamura-ku, Nagoya-shi, Aichi 450-0003
Tel. +81-52-589-6511  Fax. +81-52-589-6512

**Osaka Branch**
PACASSO MIKUINI Building 4th floor, 3-9-14 Nittaka, Yodogawa-ku, Osaka-shi, Osaka 532-0033
Tel. +81-6-6150-5520  Fax. +81-6-6150-5530

**Chushikoku Branch**
Nihon Seimei Hiroshima Hikari-machi Building 4th floor, 1-10-19 Hikari-machi, Hiroshima-ku, Hiroshima-shi, Hiroshima 732-0052
Tel. +81-82-264-3366  Fax. +81-82-263-7712

**Kyushu Branch**
Fukuoka Building, 2-Wing 6th floor, 2-10-1 Hakata-Eki Higashi, Hakata-ku, Fukuoka-shi, Fukuoka 812-0013
Tel. +81-9-472-5661  Fax. +81-9-474-8555

**Shanghai Representative Office**
Room C-901, Orient International Building (Part C), No.85 Lou Shan Guan Road, Shanghai, China (PC 200336)
Tel. +86-21-6278-7686  Fax. +86-21-6278-7687

---

**Corporate Outlook**

**Corporate Name:** Fujirebio Inc.

**Headquarters:** Shinjuku Mitsui Building 8th floor, 2-1-1 Nishishinjuku, Shinjuku-ku, Tokyo 163-0410

**Telephone:** +81-3-6279-0800

**Representative:** Yoshihiro Ashihara, President & CEO

**Foundation:** July 1, 2005 (Corporate Split)
December 18, 1950 (Before corporate split)

**Paid-in Capital:** 4,252 million yen

**Business Activities:** Manufacturing, sales, import and export of diagnostics and assay instrument

**Number of Employees:** 575 (as of March 31, 2016)

**Board Members:**
- President & CEO: Yoshihiro Ashihara
- Representative Managing Director: Goki Ishikawa
- Directors: Hiromasa Suzuki, Naoyoshi Kubota, Akira Suenaga, Masayuki Nagasaki, Katsumi Aoyagi, Shigekazu Takeuchi
- Statutory Auditor: Toyoki Masada
- Auditors: Ikuo Mashimo, Koichi Tsuji

---

**Subsidiaries**

**Advanced Life Science Institute, Inc.**
51 Komiya-machi, Hachioji-shi, Tokyo 192-0031, Japan
Tel. +81-4-649-8230 Fax. +81-4-649-8231

**Fujirebio America, Inc.**
2751 Centerville Road, Wilmington, DE 19808-1627 U.S.A.

**Fujirebio Diagnostics, Inc.**
201 Great Valley Parkway, Malvern, PA 19355-1308, U.S.A.
Tel. +1-610-240-3800  Fax. +1-484-772-8013

**Fujirebio Diagnostics AB**
Majabgetherminalen 414 55 Gothenburg, Sweden
Tel. +46-31-85-70-30 Fax. +46-31-85-70-40

**Fujirebio Europe N.V.**
Technologiepark 6
B-9052 Gent, Belgium
Tel. +32-9-329-13-29  Fax. +32-9-329-19-11

**Fujirebio Taiwan Inc.**
No.391, Sec.1, Heiping W. Rd., Dayuan District, Taoyuan City, Taiwan, R.O.C.
Tel. +886-3-386-5117  Fax. +886-3-386-5118
Fujirebio Inc.

- JR, Odakyu, and Keio Lines: 6-minute walk from Shinjuku Station
- Tokyo Metro Marunouchi Line: 2-minute walk from Nishi Shinjuku Station
- Toei Subway Oedo Line: 1-minute walk from Tochomae Station
- Toei Subway Shinjuku Line: 11-minute walk from Shinjuku Station

Fujirebio Inc. is a member of Miraca Group.

Published on November 1, 2016

Environmental concerns in creation and printing of this booklet

FSC® Paper from responsible sources

Vegetable oil ink

MIX

Published on November 1, 2016